Prosoma Digital Therapeutics, EVERSANA | September 27, 2022
Prosoma Digital Therapeutics, innovators in reinventing healthcare for oncology patients, has partnered with EVERSANA®, a pioneer of next-generation commercial services to the global life sciences industry, to support the expected launch and commercialisation for Prosoma's digital therapy to support the mental health of cancer patients.
The digital therapy, Living Well, is the company's proprietary application designed to improve the quality of life and reduce stress, anxiety, and depression symptoms related to cancer diagnosis and treatment.EVERSANA's leading experts in launching and commercialising digital therapeutic solutions will help Prosoma navigate regulatory pathways and plan for commercialisation.
"As we looked to navigate the complexity of commercialising our digital solutions in the United States, it became clear we need a partner with the infrastructure and experience to help us move quickly," said Andrzej Jonczyk, Chief Executive Officer, Prosoma U.S.
"As we looked to navigate the complexity of commercialising our digital solutions in the United States, it became clear we need a partner with the infrastructure and experience to help us move quickly," said Andrzej Jonczyk, Chief Executive Officer, Prosoma U.S. "As we spoke with partners across Europe and the world, one name continued to rise to the top and that was EVERSANA. Their integrated platform and deep experience in digital therapeutics make them the perfect partner to help bring our important therapies to patients."
"The future of healthcare continues to evolve as innovative solutions improve the patient journey," said Jim Lang, CEO, EVERSANA. "EVERSANA was built with this in mind. By helping Prosoma, we will provide critical mental health support for cancer patients and caregivers through this novel approach to digital therapy."
EVERSANA and Prosoma Digital Therapeutics will attend and be available to discuss the partnership at the 5th annual DTx East Conference, September 27-29 in Boston, Massachusetts.
ABOUT Prosoma Digital Therapeutics
As a global leader in Digital Therapeutics for oncology, Prosoma provides patients with comprehensive solutions that are fully tailored to their medical conditions. The company created a portfolio of medical software products by combining world-leading expertise in medicine and technology and covering cancer patients' entire behavioural support needs. The company's flagship product, Living Well App, leads the patient from the moment of diagnosis towards regaining control over their wellbeing. It helps patients deal with their emotions and stress, build healthy habits and support them through their recovery process. The Living Well App is already reimbursed by healthcare insurance companies in Germany, and Prosoma is also aiming to have the costs of its products covered by healthcare systems in the US, the UK, and Poland. To learn more about Promosa, visit http://www.prosoma.com or connect through LinkedIn
EVERSANA™ is the leading independent provider of global services to the life sciences industry. The company's integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including innovative start-ups and established pharmaceutical companies, to advance life sciences solutions for a healthier world. To learn more about EVERSANA, visit eversana.com or connect through LinkedIn and Twitter.
Grip Security | September 27, 2022
Grip is looking to add partners who understand the differentiated value of their offering, and the uniqueness that it will provide to customers looking for improved SaaS security.
Grip Security, which makes a SaaS security solution that unifies discovery, access control and data governance, has announced the Grip Security Partner Program.
Grip emerged from stealth in April 2021 with a SaaS security solution designed to go beyond the limits of traditional CASBs, while at the same time making it easy to cover a large number of apps, overcoming a problem that exploded with the number of apps where many apps were simply not covered.
“The company has grown by 300% and has seen a 500% growth in engagements with Fortune 500 companies,” said Lior Yaari, Grip Security’s CEO.
“The company has grown by 300% and has seen a 500% growth in engagements with Fortune 500 companies,” said Lior Yaari, Grip Security’s CEO. “There has been a lot of change and a lot market change.”
Because SaaS is closely tied to identity, Grip made it a top priority to establish deep integrations with as many identity providers as possible. That phase has now been completed.
“We have extended our integration to almost every identity provider in the market today – almost a dozen,” Yaari said. “We are now looking at bringing joint offerings with large security vendors to market. Many of these joint integrations have been signed, but have not yet been announced, as we are still building out joint value.”
Grip started out briefly selling direct in their proof of concept stage, but the pivot to the channel was in their plans, and that too has already taken place.
“We have a channel-focused Go-to-Market strategy,” Yaari stated. “14 is the number of partners that we have right now, and that is growing fast. Our third U.S. hire was our director of channel sales. This is a critical part of our strategy.”
The plan is for a fairly rapid channel expansion, not just to work with a small number of partners until they become successful.
“We aren’t looking to work with 10,000 partners, but we do want to find enough key partners,” Yaari indicated. “We are not looking for logos on the web site. We are looking for partners who want to work with us so that we can make each other successful, and where they can position themselves as a source of innovation with us.”
Insight is one of their initial partners.
“With Insight, we are not part of a special innovation program,” Yaari said. “They are an example of a partner that we have a good relationship with, who understand how to drive need and who knows that SaaS is becoming bigger.”
The problem many partners face is that since SaaS is relatively new, as they think organizations don’t have the right solutions to fix it, and they themselves lack the right backdrop for channel sales to explain it to the customer.
“For the partner, they keys are understanding the problem space, understanding the market and the patching that is used today, and understanding how we are unique and the right questions to ask to get a meeting,” Yaari said.
The program begins with a single tier, but Yaari said that they intended to expand that as the program builds out further.
Simplicity is a dominant feature of the new program.
“Our product is very different from other security products,” said Young-Sae Song, Chief Marketing Officer at Grip. “It takes 10 minutes to install. It is simple enough to be demoed by a channel sales person. You don’t need a technical person with deep training to demo it.” Grip also supports partners with jointly funded programs to promote Grip, as well as co-branded sales materials.
Song said that because Grip isn’t heavy like most SaaS solutions, the channel can go to market very quickly with it.
“It is probably faster for them than any other enterprise security product,” he stated.
It also provides support for more than 20,000 SaaS applications, allows for 80% reduction in analyst workload, and has five times more SaaS application discovery compared to CASBs.
AscellaHealth | September 26, 2022
AscellaHealth, a global healthcare and specialty pharmacy solutions company, is extremely honored to be named Strategic Channel Partner of the Year at the recent National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo. This award is given to an organization such as a manufacturer, technology provider, GPO, Hub service provider, logistics provider, nonprofit or other that provides a service or solution to facilitate the delivery of high-quality, cost-effective specialty pharmacy care.
Honored to receive this award, Dea Belazi, president and CEO, AscellaHealth says, "This extraordinary recognition by such an esteemed organization as NASP belongs to our talented team of strategic innovators with unparalleled industry experience and expertise. It is extremely gratifying to gain this unique distinction in the specialty pharmacy market and our entire organization is deserving of this hon
Honored to receive this award, Dea Belazi, president and CEO, AscellaHealth says, "This extraordinary recognition by such an esteemed organization as NASP belongs to our talented team of strategic innovators with unparalleled industry experience and expertise. It is extremely gratifying to gain this unique distinction in the specialty pharmacy market and our entire organization is deserving of this honor.”
AscellaHealth is part of The AscellaHealth Family of Companies: including subsidiaries Optime Care dedicated to rare, orphan/ultra-orphan disease patients and Terebellum, a global organization serving pharmaceutical manufacturers.
Belazi continues, "The AscellaHealth Family of Companies provide single-source, end-to-end solutions to tighten the specialty pharmacy value chain. In the highly fragmented current marketplace with multiple vendors handling each stage of the pre-launch, commercialization, distribution and fulfilment processes, manufacturers value our one stop, consultative approach. Most importantly, we are always mindful of putting patients at the center of all our initiatives."
With a focus on optimizing access to expensive specialty and rare disease medications and improving patient outcomes, AscellaHealth provides a full spectrum of cutting-edge programs and services that are valued by all stakeholders, including patients, payers, life sciences manufacturers and providers. AscellaHealth core services include pre-commercialization and market access, comprehensive Hub and patient support, exclusive distribution partnerships and national specialty medication fulfillment, data analytics, supply chain logistics and payer/pharmaceutical financial solutions.
To learn more about AscellaHealth’s unique life sciences solutions, email email@example.com
About AscellaHealth LLC
AscellaHealth is a global Healthcare & Specialty Pharmacy solutions organization serving patients, payers, life sciences manufacturers and providers, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and personalized medical management services. A multiple Inc. 5000 winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Most recently, AscellaHealth has joined with its subsidiaries, Optime Care and Terebellum to form the AscellaHealth Family of Companies. Visit www.AscellaHealth.com.